Oral contraceptives and intrauterine devices as risk factors for breast and cervical cancers: a systematic review
DOI:
https://doi.org/10.18203/2320-6012.ijrms20202294Keywords:
Breast cancer, Cervical cancer, Intrauterine devices, Levonogestrel, Oral contraceptives, Risk factorAbstract
Breast and cervical cancers have commandingly become major public health threats across the world. While studies have reported on the nexus between the use of oral contraceptives (OCs) and intrauterine devices (IUDs) as risk factors for breast and cervical cancers, there exists a paucity of explicit data on the nature of the association. Authors report the effect of oral contraceptives and the use of IUDs on the development of breast and cervical cancers. Several databases (Cochrane Library, Google Scholar and PubMed) were searched using well-specified criteria and a total of 15 papers selected. Meta-analyses, systematic reviews and studies that used cross-sectional designs were excluded from the review. Three and twelve cohort and case-control studies were reviewed respectively. Four of these studies reported an increased association between oral contraceptives and the risk of cervical cancer while nine showed positive correlation between oral contraceptives and risk of breast cancer. One study showed association between levonogestrel IUDs and risk of breast cancer while the other study did not show association between both levonogestrel and copper IUDs with risk of breast cancer. Use of copper IUDs was associated with diminishing risk of cervical cancer. Overall, use of oral contraceptives upsurges risk of breast and cervical cancers especially when used for longer periods of time. Further studies should therefore be done to understand the mechanisms of action of oral contraceptives and IUDs on the development of both cancers.
References
World Health Organization. Global status report on alcohol and health 2018. World Health Organization; 2019 Feb 14.
Azubuike SO, Muirhead C, Hayes L, McNally R. Rising global burden of breast cancer: the case of sub-Saharan Africa (with emphasis on Nigeria) and implications for regional development: a review. World J Surg Oncol. 2018;16(1):63.
United Nations. Contraceptive Use by Method 2019: Data Booklet, UN, New York. 2019; 1-28. Available at: https://www.un.org/en/development/desa/population/publications/dataset/contraception/wcu2019.asp/. Accessed 22 May 2020.
World Health Organization. Family planning/contraception. WHO. World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs351/e. Accessed September 2018.
Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. 2017;389(10071):847-60.
Spevack E. The long-term health implications of depo-provera. Integrat Medi. 2013 Feb;27.
Reyes HD, Carlson M, McDonald M, Zhang Y, Dai D, Yang S, et al. The effect of progesterone-containing intrauterine device on hormone receptor expression of the endometrium. Gynecolog Oncol. 2014;135(2):398.
Trading Economics. Contraceptive prevalence (% of women ages 15-49) in Kenya. 2020; Available at: https://tradingeconomics.com/kenya/contraceptive-prevalence-percent-of-women-ages-15-49-wb-data.html. Accessed 22 May 2020.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. System Rev. 2015;4(1):1.
Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin‐only pills for contraception. Cochran Datab System Rev. 2010(1).
Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. New Engl J Medi. 2017;377(23):2228-39.
Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, Palmer JR. Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. Cancer Epidemiol Prevent Biomark. 2010;19(8):2073-9.
Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat. 2014;143(3):579-86.
Roy AG, Sarkar BN, Bandyopadhyay AR. Oral Contraceptives and Breast Cancer Risk: A Study among the Bengalee Females of West Bengal, India. 2018.
Bardaweel SK, Akour AA, Al-Muhaissen S, AlSalamat HA, Ammar K. Oral contraceptive and breast cancer: do benefits outweigh the risks? A case–control study from Jordan. BMC Women's Health. 2019;19(1):72.
Urban M, Banks E, Egger S, Canfell K, O'Connell D, Beral V, et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLoS Medi. 2012;9(3).
Vaisy A, Lotfinejad S, Zhian F. Risk of cancer with combined oral contraceptive use among Iranian women. Asian Pacific J Cancer Prevent. 2014;15(14):5517-22.
Poosari A, Promthet S, Kamsa-Ard S, Suwanrungruang K, Longkul J, Wiangnon S. Hormonal contraceptive use and breast cancer in Thai women. J Epidemiol. 2014;24(3):216-20.
Karim SM, Baeshen W, Neamatullah SN, Bin B. Oral contraceptives, abortion and breast cancer risk: a case control study in Saudi Arabia. Asian Pac J Cancer Prev. 2015;16(9):3957-60.
Ichida M, Kataoka A, Tsushima R, Taguchi T. No increase in breast cancer risk in Japanese women taking oral contraceptives: a case-control study investigating reproductive, menstrual and familial risk factors for breast cancer. Asian Pac J Cancer Prev. 2015;16(9):3685-90.
Dinger J, Bardenheuer K, Do Minh T. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception. 2011;83(3):211-7.
Catherino W, Jeng M, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer. 1993;67(5):945-52.
Paramita S, Soewarto S, Widodo MA, Sumitro SB. High parity and hormonal contraception use as risk factors for cervical cancer in East Kalimantan. Med J Indines. 2010;19:268-72.
Roura E, Travier N, Waterboer T, de Sanjosé S, Bosch FX, Pawlita M, et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort. PLoS One. 2016;11(1):e0147029.
Chagas B, Gurgel A, Lima R, Cordeiro M, Moura R, Coelho A, et al. Synergic effect of oral contraceptives, GSTP1 polymorphisms, and high-risk HPV infection in development of cervical lesions. Genet Molecu Res. 2017;16(3).
Gao T, Wang J, Yang M, Li H. Transcriptome analysis reveals the effect of oral contraceptive use on cervical cancer. Molec Medi Rep. 2014;10(4):1703-8.
Bassuk SS, Manson JE. Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. Ann Epidemiol. 2015;25(3):193-200.
Averbach S, Silverberg MJ, Leyden W, Smith-McCune K, Raine-Bennett T, Sawaya GF. Recent intrauterine device use and the risk of precancerous cervical lesions and cervical cancer. Contraception. 2018;98(2):130-4.
Cortessis VK, Barrett M, Wade NB, Enebish T, Perrigo JL, Tobin J, et al. Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstetr Gynecol. 2017;130(6):1226-36.
Castellsagué X, Díaz M, Vaccarella S, de Sanjosé S, Muñoz N, Herrero R, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol. 2011;12(11):1023-31.
Figueiredo JC, Haile RW, Bernstein L, Malone KE, Largent J, Langholz B, et al. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Res Treat. 2010;120(1):175-83.
